iwCLL 2017 | Can ibrutinib be used as a first-line treatment in CLL?
Stephan Stilgenbauer, MD from Ulm University, Ulm, Germany discusses the advances in novel chronic lymphocytic leukemia (CLL) treatments, a hot topic at the International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2017, New York, NY. BTK inhibitor ibrutinib is an excellent example of a novel agent that successfully targets the biology of CLL. Prof. Stilgenbauer describes the advantages of ibrutinib in high-risk disease patients and those who have failed chemo-immunotherapy as a front-line treatment. The next question for ibrutinib is whether it can be used as a front-line treatment in younger patients who have not received any treatment.
Get great new content delivered to your inboxSign up